{"id":903836,"date":"2025-10-31T16:40:08","date_gmt":"2025-10-31T20:40:08","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-14\/"},"modified":"2025-10-31T16:40:08","modified_gmt":"2025-10-31T20:40:08","slug":"neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-14","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-14\/","title":{"rendered":"Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)"},"content":{"rendered":"
\n

MALVERN, Pa., Oct. 31, 2025 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards to twelve new employees as described below. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by Neuronetics\u2019 Compensation Committee and made as a material inducement to their respective employment with the Company. In all cases, vesting is subject to the recipient\u2019s continued service with the Company through the applicable vesting date, and the awards are subject to the terms of the Company\u2019s 2020 Inducement Incentive Plan.<\/p>\n

\n Restricted stock units (\u201cRSUs\u201d)\u00a0<\/strong>\n <\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Name\u00a0<\/td>\nNumber of Inducement Plan RSUs\u00a0<\/td>\nVesting Schedule\u00a0<\/td>\n<\/tr>\n
William Kyle\u00a0<\/td>\n1,500<\/td>\n1\/3 on first anniversary of grant date; 1\/3 on second anniversary of grant date; 1\/3 on third anniversary of grant date, subject in each case to the recipient\u2019s continued employment by the Company through the applicable vesting date.<\/td>\n<\/tr>\n
Ryan McCarthy<\/td>\n1,500<\/td>\n1\/3 on first anniversary of grant date; 1\/3 on second anniversary of grant date; 1\/3 on third anniversary of grant date, subject in each case to the recipient\u2019s continued employment by the Company through the applicable vesting date.<\/td>\n<\/tr>\n
Cheyenne Chaltraw<\/td>\n1,500<\/td>\n1\/3 on first anniversary of grant date; 1\/3 on second anniversary of grant date; 1\/3 on third anniversary of grant date, subject in each case to the recipient\u2019s continued employment by the Company through the applicable vesting date.<\/td>\n<\/tr>\n
Shekenah Lee<\/td>\n1,500<\/td>\n1\/3 on first anniversary of grant date; 1\/3 on second anniversary of grant date; 1\/3 on third anniversary of grant date, subject in each case to the recipient\u2019s continued employment by the Company through the applicable vesting date.<\/td>\n<\/tr>\n
Cole Uphoff<\/td>\n1,500<\/td>\n1\/3 on first anniversary of grant date; 1\/3 on second anniversary of grant date; 1\/3 on third anniversary of grant date, subject in each case to the recipient\u2019s continued employment by the Company through the applicable vesting date.<\/td>\n<\/tr>\n
Amber Bruce<\/td>\n1,500<\/td>\n1\/3 on first anniversary of grant date; 1\/3 on second anniversary of grant date; 1\/3 on third anniversary of grant date, subject in each case to the recipient\u2019s continued employment by the Company through the applicable vesting date.<\/td>\n<\/tr>\n
Roopam Verma<\/td>\n4,500<\/td>\n1\/3 on first anniversary of grant date; 1\/3 on second anniversary of grant date; 1\/3 on third anniversary of grant date, subject in each case to the recipient\u2019s continued employment by the Company through the applicable vesting date.<\/td>\n<\/tr>\n
Bhupinder Singh<\/td>\n11,250<\/td>\n1\/3 on first anniversary of grant date; 1\/3 on second anniversary of grant date; 1\/3 on third anniversary of grant date, subject in each case to the recipient\u2019s continued employment by the Company through the applicable vesting date.<\/td>\n<\/tr>\n
Bhupinder Singh<\/td>\n7,500<\/td>\n1\/3 on second anniversary of grant date; 1\/3 on third anniversary of grant date; 1\/3 on fourth anniversary of grant date, subject in each case to the recipient\u2019s continued employment by the Company through the applicable vesting date.<\/td>\n<\/tr>\n
Katherine Kile<\/td>\n1,500<\/td>\n1\/3 on first anniversary of grant date; 1\/3 on second anniversary of grant date; 1\/3 on third anniversary of grant date, subject in each case to the recipient\u2019s continued employment by the Company through the applicable vesting date.<\/td>\n<\/tr>\n
Agmarillis Vanga De Hoyos<\/td>\n4,500<\/td>\n1\/3 on first anniversary of grant date; 1\/3 on second anniversary of grant date; 1\/3 on third anniversary of grant date, subject in each case to the recipient\u2019s continued employment by the Company through the applicable vesting date.<\/td>\n<\/tr>\n
Thomas Coles<\/td>\n600<\/td>\n1\/3 on first anniversary of grant date; 1\/3 on second anniversary of grant date; 1\/3 on third anniversary of grant date, subject in each case to the recipient\u2019s continued employment by the Company through the applicable vesting date.<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n<\/table>\n

\n About Neuronetics <\/strong>
\n
Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is delivering more treatment options to patients and physicians by offering exceptional in-office treatments that produce extraordinary results. NeuroStar Advanced Therapy is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication has not helped. In addition to selling the NeuroStar Advanced Therapy System and associated treatment sessions to customers, Neuronetics operates Greenbrook TMS Inc. (Greenbrook) treatment centers across the United States, offering NeuroStar Advanced Therapy for the treatment of MDD and other mental health disorders. NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults, with more than 7.6 million treatments delivered, and is backed by the largest clinical data set of any TMS treatment system for depression, including the world\u2019s largest depression outcomes registry. Greenbrook treatment centers also offer SPRAVATO\u00ae (esketamine) Nasal Spray, a prescription medicine indicated for the treatment of treatment-resistant depression (TRD) in adults as monotherapy or in conjunction with an oral antidepressant. It is also indicated for depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior in conjunction with an oral antidepressant.1<\/sup> Greenbrook has provided more than 1.8 million treatments to over 55,000 patients struggling with depression.<\/p>\n

The NeuroStar Advanced Therapy System is cleared by the U.S. Food and Drug Administration for adults with MDD, as an adjunct for adults with obsessive-compulsive disorder, to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression), and as a first line adjunct for the treatment of MDD in adolescent patients aged 15-21. For safety information and indications for use, visit NeuroStar.com. <\/strong><\/p>\n

\n Investor Contact:<\/strong>
\n
Mike Vallie or Mark Klausner
ICR Healthcare
443-213-0499
ir@neuronetics.com<\/strong><\/a><\/p>\n

\n Media Contact:<\/strong>
\n
EvolveMKD
646-517-4220
NeuroStar@evolvemkd.com<\/strong><\/a><\/p>\n

__________________________<\/p>\n

\n 1<\/sup>\u00a0The effectiveness of SPRAVATO\u00ae<\/sup>\u00a0in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated. Use of SPRAVATO\u00ae<\/sup>\u00a0does not preclude the need for hospitalization if clinically warranted, even if patients experience improvement after an initial dose of SPRAVATO\u00ae<\/sup>. For more important safety information about SPRAVATO\u00ae<\/sup>, please visit\u00a0spravatohcp.com<\/strong><\/a>.<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

MALVERN, Pa., Oct. 31, 2025 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards to twelve new employees as described below. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by Neuronetics\u2019 Compensation Committee and made as a material inducement to their respective employment with the Company. In all cases, vesting is subject to the recipient\u2019s continued service with the Company through the applicable vesting date, and the awards are subject to the terms of the Company\u2019s 2020 Inducement Incentive Plan. Restricted stock units (\u201cRSUs\u201d)\u00a0 Name\u00a0 Number … <\/p>\n

Continue reading “Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-903836","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nNeuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-14\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"MALVERN, Pa., Oct. 31, 2025 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards to twelve new employees as described below. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by Neuronetics\u2019 Compensation Committee and made as a material inducement to their respective employment with the Company. In all cases, vesting is subject to the recipient\u2019s continued service with the Company through the applicable vesting date, and the awards are subject to the terms of the Company\u2019s 2020 Inducement Incentive Plan. Restricted stock units (\u201cRSUs\u201d)\u00a0 Name\u00a0 Number … Continue reading "Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-14\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-31T20:40:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NjMwNiM3MjM2OTk4IzIxMTA0NDA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-14\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-14\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)\",\"datePublished\":\"2025-10-31T20:40:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-14\\\/\"},\"wordCount\":955,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-14\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2NjMwNiM3MjM2OTk4IzIxMTA0NDA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-14\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-14\\\/\",\"name\":\"Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-14\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-14\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2NjMwNiM3MjM2OTk4IzIxMTA0NDA=\",\"datePublished\":\"2025-10-31T20:40:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-14\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-14\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-14\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2NjMwNiM3MjM2OTk4IzIxMTA0NDA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2NjMwNiM3MjM2OTk4IzIxMTA0NDA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-14\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-14\/","og_locale":"en_US","og_type":"article","og_title":"Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","og_description":"MALVERN, Pa., Oct. 31, 2025 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards to twelve new employees as described below. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by Neuronetics\u2019 Compensation Committee and made as a material inducement to their respective employment with the Company. In all cases, vesting is subject to the recipient\u2019s continued service with the Company through the applicable vesting date, and the awards are subject to the terms of the Company\u2019s 2020 Inducement Incentive Plan. Restricted stock units (\u201cRSUs\u201d)\u00a0 Name\u00a0 Number … Continue reading \"Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-14\/","og_site_name":"Market Newsdesk","article_published_time":"2025-10-31T20:40:08+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NjMwNiM3MjM2OTk4IzIxMTA0NDA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-14\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-14\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)","datePublished":"2025-10-31T20:40:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-14\/"},"wordCount":955,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-14\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NjMwNiM3MjM2OTk4IzIxMTA0NDA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-14\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-14\/","name":"Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-14\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-14\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NjMwNiM3MjM2OTk4IzIxMTA0NDA=","datePublished":"2025-10-31T20:40:08+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-14\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-14\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-14\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NjMwNiM3MjM2OTk4IzIxMTA0NDA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NjMwNiM3MjM2OTk4IzIxMTA0NDA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuronetics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-14\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/903836","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=903836"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/903836\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=903836"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=903836"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=903836"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}